AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04931420
Drug: Standard of Care Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * If you have cancer of the stomach or food pipe (esophagus): the preferred chemotherapy regimen includes two or three medications. These drugs include Cisplatin or Oxaliplatin and 5-fluorouracil (5 FU) in combination with Docetaxel.~* If you have cancer of the pancreas or ampulla: the preferred chemotherapy medicines include Gemcitabine or a three-drug combination chemotherapy called FOLFIRINOX, which includes 5FU, Leucovorin, Irinotecan, and Oxaliplatin.~* If you have bile duct cancers: a combination of Gemcitabine, platinum agents, or fluoropyrimidine will be considered.
Trial: NCT05766501
Drug: DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
Trial: NCT06220279
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each were monitored for pain within 24 hours
Trial: NCT05669599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo by SC injection.
Trial: NCT05363891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03877874
Drug: Aironyl syrup(Terbutaline sulfate) + Epidrone syrup(Dexamethone)
RxNorm normalized name: nafronyl
DrugBank: Naftidrofuryl (DB13588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aironyl syrup(Terbutaline sulfate ................. 1.5mg) 0.075-0.29 mg/ kg body weight 3 times daily Apidone syrup(Dexamethone) (0.02 to 0.3 mg per kilogram (kg) of body weight per day, divided and taken 3 or 4 times a day)
Trial: NCT05232045
Drug: Automated urinary output collection system group (tight monitoring of urine output)
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated urinary output collection system group (tight monitoring of urine output)
Trial: NCT05806359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05092711
Drug: Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Using INTERASPIRE model to determine patients with established CHD whether the guidelines on cardiovascular disease prevention are being followed or not with incorporation of COVID 19 as a risk factor with the other classical risk factors to understand significance of the new pandemic virus in mortality and morbidity of CVD and coronary events in association with the other known classical risk factors .
Trial: NCT05970718
Drug: REGN7544
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for single ascending Intravenous (IV) or Subcutaneous (SC) administration
Trial: NCT05970718
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for single ascending IV or SC administration per the protocol
Trial: NCT05605756
Drug: OnabotulinumtoxinA 145 UNT [Botox]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum A toxin injection: Will follow the FDA-approved guideline of the treatment of chronic migraine. The following modifications are planned: (a) Total units 145 instead of 155. (b) Number of injection sites 29 instead of 31. (c) the 6 injection sites in the trapezius muscle will be eliminated as they are irrelevant to our attempt to reduce seizure events. Instead, 4 injections will be made subcutaneously along the superior sagittal suture (see figures below), where no muscles exist and thus no muscle weakness is likely. This dose (145 Units) is well below the FDA-approved guideline on safety for adolescents and adults (no more than 10 Units/Kg or a total of 340 Units).~Botox injections will take place in the BIDMC Headache Clinic which is a part of the Arnold Pain center at 1 Brookline Place. Injections will be administered by Dr. Sait Ashina, the Director of the Headache Clinic.
Trial: NCT06189495
Drug: GenSci048
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of Genakumab injection every 4 weeks according to their group.The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with Genakumab injection until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive Genakumab injection 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel
Trial: NCT06189495
Drug: GenSci048 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Dosage: 300 mg.2. Duration of administration: All subjects received one dose of placebo every 4 weeks according to their group The dose was injected subcutaneously.3. Course of administration: Phase I subjects were treated with placebo until the end of the study or the occurrence of the drug.Tolerable toxicity or investigator-assessed efficacy (whichever occurs first); The phase 2 randomized double-blind treatment period was 24 weeks, with a total of 6 administration times. After the randomized double-blind treatment period, an open-label treatment period was entered, and all subjects will receive placebo 300 mg Q4W until the end of the study or the occurrence of intolerable toxicity or poor efficacy assessed by the investigators (whichever occurs first).~4. Administration method: subcutaneous injection; The injection site is the abdomen (3 cm away from the navel)
Trial: NCT05688852
Drug: VTX958
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose B VTX958
Trial: NCT05688852
Drug: VTX958 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04979572
Drug: TS-172
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single doses of TS-172 10 mg, 30 mg, 90 mg, 270 mg before breakfast in each period (only 30 mg administered before breakfast and fasting)~* Multiple dose of TS-172 90 mg before breakfast and dinner
Trial: NCT04979572
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Single doses of TS-172 placebo before breakfast in each period (only placebo administered before breakfast and fasting in step 2)~* Multiple dose of TS-172 placebo before breakfast and dinner
Trial: NCT04512716
Drug: 131-I Apamistamab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 131-I apamistamab 5-7 days prior to a single infusion of 1x10\^6 19-28z CAR T-cells/kg for those in the B-ALL cohort, or 2x10\^6 19-28z CAR T-cells/kg, for those in the DLBCL. 131-I apamistamab may be administered inpatient or outpatient at the discretion and judgment of the treating investigators.
Trial: NCT06011577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet
Trial: NCT05745727
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8
Trial: NCT06364800
Drug: targeted drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-target kinase inhibitors can act on VEGFR-1,VEGFR-2,VEGFR-3,FGFR1,PDGFR,cKit,Ret and other targets.
Trial: NCT05617820
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal Insert, 4 mcg tablet
Trial: NCT05617820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle Vaginal Insert
Trial: NCT06558253
Drug: Coenzyme I for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received 21 consecutive days of intravenous infusion of Coenzyme I for injection, starting from the day of transplantation , and then continuously applied intravenously until 20 days post transplantation, with three dose groups: subjects #1-3 received one intravenous infusion per day containing 10 mg of Coenzyme I for injection, subjects #4-6 received one intravenous infusion per day containing 20 mg of Coenzyme I for injection, and subjects #7-12 received one intravenous infusion per day containing 50 mg of Coenzyme I for injection. Subjects in either dose group experienced a treatment-related Grade 3 or higher adverse reaction, the previous dose group was the maximum tolerated dose.
Trial: NCT04964934
Drug: AZD9833
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage formulation: AZD9833 tablets will be administered orally
Trial: NCT04964934
Drug: AZD9833 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage formulation: AZD9833 placebo tablets will be administrated orally.
Trial: NCT06276231
Drug: Diclofenac Injection
RxNorm normalized name: diclofenac Injection
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg of Diclofenac intramuscular Injection
Trial: NCT04834557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered to the control group for 24 weeks as an add-on treatment to the current DMARDs treatments for rheumatoid arthritis.
Trial: NCT05630755
Drug: DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOR/ISL 100 mg/0.25 mg oral tablets once daily
Trial: NCT05630755
Drug: BIC/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
Trial: NCT05630755
Drug: Placebo to BIC/FTC/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral tablets once daily
Trial: NCT05630755
Drug: Placebo to DOR/ISL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg oral tablets once daily
Trial: NCT05115942
Drug: The placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After randomization, The control group were orally received placebo capsules at a daily dose of 270 mg, 3 capsules each time, t.i.d, 30 min before meals for 52 weeks.
Trial: NCT05005078
Drug: WST-057
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WST-057 topical solution
Trial: NCT05005078
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WST-057 Matching placebo
Trial: NCT05504395
Drug: CSTI-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10 mg capsule
Trial: NCT05216614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lactose placebo capsules identical to fluvoxamine capsules in order to preserve blind
Trial: NCT04998006
Drug: Alcohol and Cannabis vs. Alcohol only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-directed (ad-libitum) cannabis and alcohol vs. self-direct (ad-libitum) alcohol
Trial: NCT06419621
Drug: PM8002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
Trial: NCT06419621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
Trial: NCT05835206
Drug: Microbiome Therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single course of study treatment (IP, Encapsulated Microbiota): Orally delivered, non-frozen, encapsulated investigational intestinal microbiota, consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14.
Trial: NCT05835206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single course of study treatment (Color-matched placebo capsules containing microcrystalline cellulose (MCC) powder), consisting of 16 capsules. One dose (8 capsules) is administered daily (QD) for 2 days. The capsules are to be taken orally with water on an empty stomach. Each dose will be taken approximately every 24 hours, with a minimum of 12 hours from the previous dose to a maximum of 36 hours. Both doses must be completed within the stated 36 hours ±12 hours. Depending on the time of the first dose, dosing may occur over 3 calendar days.~A second cycle will begin and a second treatment will be given if the participant is still MDRO positive on Day 14 of Cycle 1. If applicable, Cycle 2 will begin within 7 days of Day 14.
Trial: NCT05613166
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C
Trial: NCT04574778
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of oral acetaminophen preoperatively administered
Trial: NCT06624670
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone
Trial: NCT06259981
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 placebo capsules orally twice daily
Trial: NCT06481488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2086 matched placebo tablets.
Trial: NCT04790305
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects in the experimental group will be treated with Huaier Granule continuously for 2 years or until the disease progressed, intolerable toxicity, withdrawal of informed consent form or died for any reason.
Trial: NCT04649476
Drug: Camrelizumanb plus TPF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants will receive camrelizumab (200 mg) through intravenous infusion each 2-week cycle, and docetaxel (T) 75 mg/m2, cisplatin (P) 75 mg/m2, 5-Fluorouracil (F) 750 mg/m2 through intravenous infusion each 3-week cycle for 2 cycles.
Trial: NCT05741372
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin
Trial: NCT05570383
Drug: Dust mite drops (trade name: Changdi, Zhejiang Tawu Biotechnology Co. Ltd.).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will be with Sublingual immunotherapy (trade name: Changdi, Zhejiang Tawu Biotechnology Co., Ltd.). The control group will be with Mometasone Furoate Aqueous Nasal Spray (NASUNA); The treatment course of the two groups will be 3 months.
Trial: NCT05164250
Drug: REGN5458
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05220917
Drug: 2nd generation SU
RxNorm normalized name: SUS SCROFA EYE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any 2nd generation SU claim
Trial: NCT05045157
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: corticosteroid injection is performed
Trial: NCT04680026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT06366711
Drug: Pulsenmore device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ultrasound device for pregnancy care
Trial: NCT06379685
Drug: Systane Ultra®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propylene glycol 0.3% - Polyethylene glycol 400 0.4%. Ophthalmic solution.
Trial: NCT06518122
Drug: HCP1306
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once a day per period.
Trial: NCT06518122
Drug: RLD2302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once a day per period.
Trial: NCT06518122
Drug: RLD2102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once a day per period
Trial: NCT04925752
Drug: Placebo SC LEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via SC injections
Trial: NCT04925752
Drug: PTM F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT04925752
Drug: F/TAF (for US participants only)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F/TAF tablets administered orally once daily
Trial: NCT06007352
Drug: Gentamicin
RxNorm normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be given 120 mg of gentamicin infused in 3 L NaCl used in irrigation for ureteroscopy
Trial: NCT06636357
Drug: 50% N2O plus 50% O2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 50% N2O plus 50% O2 for 45 min
Trial: NCT06269705
Drug: TCA-IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA injection of 40 mg TCA-IR
Trial: NCT05260411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Trial: NCT04931628
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl
Trial: NCT06151392
Drug: Probiotic Formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: probiotic will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Trial: NCT06151392
Drug: Zinc
RxNorm normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc will be administered to pediatric patients with ventriculitis to study their possible effect in treatment
Trial: NCT06019507
Drug: TAC
RxNorm normalized name: TAC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppression Therapy
Trial: NCT06019507
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppression Therapy
Trial: NCT05039450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06597760
Drug: Enlicitide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 20 mg enlicitide/180 mg sodium caprate coadministered with 0.25mg Digoxin orally on Day 1, Period 2 in Arm A and on Day 1 Period 1 in Arm B.
Trial: NCT05517928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules daily that look exactly like the study drug, but contains to active ingredient
Trial: NCT03883945
Drug: AIV001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injection
Trial: NCT03883945
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intradermal injection
Trial: NCT06358313
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The rosuvastatin group consisted of 300 patients who received 40 mg daily rosuvastatin for 3 months, an open-label aspirin at a loading dose of 75 to 300 mg, and then 75 mg daily till the end of the 3 months, and open-label clopidogrel at a loading dose of 300 mg and then 75 mg daily till the end of the 3 months.
Trial: NCT05007470
Drug: VSL #3 112.5 Capsule
RxNorm normalized name: VSL #3 112.5 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3 is a commercial probiotic mixture consisting of eight bacterial strains: Four strains of Lactobacillus (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, and Lactobacillus delbrueckii subspecies bulgaricus), three strains of Bifidobacterium (Bifidobacterium breve, Bifidobacterium longum, and Bifidobacterium infantis), and one strain of Streptococcus (Streptococcus salivarius subspecies thermophilus).
Trial: NCT04826588
Drug: Methylprednisolone sodium succinate 10 mg/kg intravenously
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone sodium succinate 10 mg/kg intravenously once daily for 3 days (max 1 g per dose)
Trial: NCT06185985
Drug: SPN-812
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPN-812 (200mg to 600mg once daily)
Trial: NCT05776459
Drug: AC102 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: AC102 Single intratympanic injection
Trial: NCT05776459
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator: Prednisolone Tablets taken daily by mouth
Trial: NCT06679998
Drug: Single dose, AAPB by injection, intravenous drip.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received a single intravenous infusion of AAPB for injection. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, and each time was continuously injected for 60 min±5min.
Trial: NCT06679998
Drug: Multiple dosing, AAPB for injection, intravenous drip
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received AAPB for injection with multiple intravenous drips. Each dose of AAPB for injection was dissolved with 0.9% sodium chloride injection, the infusion volume was 100mL, once a day, 60 min±5min each time, for 7 consecutive days.
Trial: NCT04271436
Drug: [F-18] flurothymidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Radiopharmaceutical
Trial: NCT05442983
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT06558422
Drug: Growth Hormone, Human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant human growth hormone (rhGH) will be replaced at a constant rate of up to 3 ng/kg/min to maintain baseline counterregulatory response. Co-administered with octreotide and glucagon.
Trial: NCT06018337
Drug: DB-1303/BNT323
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT06018337
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT06680466
Drug: YZJ-4729
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose Group 1
Trial: NCT06680466
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo